<div id="readability-page-1"><p>Looking for top-rated stocks to buy now? Recent analyst updates highlight three companies that have earned Strong Buy ratings from Top Wall Street analysts. Each stock offers solid upside potential, supported by fresh Buy calls.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>For more stock ideas, check out TipRanks' Analyst Top Stocks tool, which tracks the latest Buy ratings from top analysts in real time.</p> <p>Here are today's top analyst-backed stock picks. Click on any ticker to research the company before deciding whether to add it to your portfolio.</p> <ul> <li><strong>Rithm Capital</strong> (RITM) – Rithm Capital is a U.S.-based asset manager focused on real estate, credit, and mortgage-related investments. Today, KBW analyst Bose George maintained a Buy rating on the stock with a price target of $14 per share. In the last three months, all four Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 32.29%.<br/></li> <li><strong>Foghorn Therapeutics</strong> (FHTX) – Foghorn Therapeutics is a clinical-stage biotech focused on gene regulation therapies for cancer. Yesterday, B. Riley Securities analyst Yuan Zhi maintained a Buy rating on the stock with a price target of $10 per share. In the last three months, all seven Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 137.07%.<br/></li> <li><strong>Nuvalent</strong> (NUVL) – Nuvalent is a clinical-stage biotech developing targeted cancer therapies. Yesterday, Truist Financial analyst Gregory Renza maintained a Buy rating on the stock. In the last three months, all 11 Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 42.44%.</li> </ul> <h2><strong>Who Are the Top Analysts?</strong> </h2> <p>TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time. </p> <p><strong>See real-time analyst rankings and learn more about the performance of Top Analysts on TipRanks' </strong><strong>Top Wall Street Analysts</strong><strong> page. </strong></p></div>

RITM

NUVL

FHTX

<p>Top analysts have given 'Strong Buy' ratings to three stocks: Rithm Capital, Foghorn Therapeutics, and Nuvalent, each with significant upside potential. Rithm Capital has a 32.29% upside, Foghorn Therapeutics 137.07%, and Nuvalent 42.44%. Analysts are ranked by TipRanks based on their rating success and returns. For more insights, TipRanks offers tools to track analyst ratings in real-time.</p>

- Recent analyst updates identify three stocks with Strong Buy ratings: Rithm Capital, Foghorn Therapeutics, and Nuvalent.  
- Rithm Capital has an implied upside of 32.29%, Foghorn Therapeutics 137.07%, and Nuvalent 42.44%, according to top analysts.  
- TipRanks provides insights into analyst rankings, highlighting success rates and the average return on ratings for informed investment decisions.

3 'Strong Buy' Stocks to Buy Today,12/18/2025, According to Top Analysts